Adaptive Biotechnologies vs ImmunityBio
ADPT and IBRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADPT and IBRX compare
ImmunityBio is the larger company, worth 2.1 times as much as Adaptive Biotechnologies ($8.8B against $4.3B).
ImmunityBio grew revenue faster over the last twelve months (193% versus 50.1% for Adaptive Biotechnologies).
Adaptive Biotechnologies keeps more of each dollar of sales as profit, with a net margin of −20.7% compared with −599% at ImmunityBio.
Adaptive Biotechnologies scores higher on the StockData Score (12 against 8 for ImmunityBio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADPT | IBRX |
|---|---|---|
| Size and price | ||
| Market cap | $4.3B | $8.8B |
| Share price | $26.64 | $8.29 |
| Change, 1 year | 58.6% | 243% |
| Change, 5 years | −27.6% | −1.3% |
| Beta (5Y) | 1.82 | 1.61 |
| Employees | 624 | 691 |
| StockData Score | ||
| Total score | 12 (better) | 8 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 3 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 13.8× (better) | 53.0× |
| P/B | 29.7× | – |
| FCF yield | −0.57% (better) | −3.3% |
| Growth | ||
| Revenue growth (TTM) | 50.1% | 193% (better) |
| Revenue growth, 5Y average | 23.0% | 185% (better) |
| Profitability | ||
| Gross margin | 75.6% | 99.3% (better) |
| Operating margin | −12.2% (better) | −152% |
| Net margin | −20.7% (better) | −599% |
| FCF margin | −7.8% (better) | −174% |
| Return on equity | −39.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −3.3× | – |
| Current ratio | 4.79 | 5.72 (better) |
| Altman Z-score | 3.01 (better) | −7.44 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.6% | 19.1% |
| Held by insiders | 22.8% | 75.3% |
| Insider net buying, 12 months | −$122M | −$8.4M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 9.6% | 47.3% |
Go deeper
- ADPT stock overview
- ADPT income statement
- ADPT valuation and score
- IBRX stock overview
- IBRX income statement
- IBRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.